The SGR-105-101 study is researching SGR-1505, an investigational study drug, to determine if SGR-1505 can help people with B-cell blood cancers. The purpose of this study is to answer the following questions:
Study participants may be able to join the study if they meet the following requirements:
Other study requirements will apply
See if you may qualifyThis is what you can expect during the SGR-1505-101 study.
A member of the study team will review the Informed Consent Form (ICF) with you, which explains the study in more detail. You must sign the ICF before receiving any Screening assessments.
You will attend a screening visit to see if you are eligible for the SGR-1505-101 study.
You will take the study medication (SGR-1505) once daily or every 12 hours for each cycle period, depending on what type of B-cell lymphoma you have. The Sponsor will inform the study doctor which dosing schedule you will belong to.
For every day that includes a study clinic visit, you will take your study drug dose at the clinic.
Study follow-ups will occur within 28 days of the last dose of the study medication. These follow-ups can be conducted over the phone.
Study survival follow-ups will occur every 3 months from end of treatment until death, lost to follow-up status, or end of study, whichever occurs first.